ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO273

A Quantitative Proteomic Study of Tolvaptan Treatment in an Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease: What Remains Altered?

Session Information

Category: Genetic Diseases of the Kidneys

  • 1101 Genetic Diseases of the Kidneys: Cystic

Authors

  • Nuñez-Gonzalez, Laura, Genetics and Developmental Biology of Kidney Diseases. Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela Clinical Hospital Complex (CHUS), Santiago de Compostela, Spain
  • Cordido, Adrian, Genetics and Developmental Biology of Kidney Diseases. Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela Clinical Hospital Complex (CHUS), Santiago de Compostela, Spain
  • Vizoso, Marta, Genetics and Developmental Biology of Kidney Diseases. Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela Clinical Hospital Complex (CHUS), Santiago de Compostela, Spain
  • Gómez García, Fernando, Genetics and Developmental Biology of Kidney Diseases. Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela Clinical Hospital Complex (CHUS), Santiago de Compostela, Spain
  • Bravo, Susana, Proteomic Platform. Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela Clinical Hospital Complex (CHUS), Santiago de Compostela, Spain
  • Rodríguez, Cándido Díaz, Genetics and Developmental Biology of Kidney Diseases. Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela Clinical Hospital Complex (CHUS), Santiago de Compostela, Spain
  • Ortiz, Alberto, Jimenez Diaz foundation. School of Medicine, Autonomous University of Madrid (UAM), Madrid, Spain
  • Garcia-Gonzalez, Miguel A., Genetics and Developmental Biology of Kidney Diseases. Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela Clinical Hospital Complex (CHUS), Santiago de Compostela, Spain
Background

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a monogenic inherited disorder caused by mutations in PKD1 and PKD2 genes, with a prevalence of 1:800 live births. It Is characterized by the presence and progressive development of fluid-filled cysts leading to end-stage renal disease. A specific antagonist of vasopressin receptor type 2 in the distal tubules of the nephron (Tolvaptan) has been approved for ADPKD treatment. Although Tolvaptan mechanism of action has been described, its underlying molecular mechanisms are not well characterized. Our study is mainly focused on the understanding of those Tolvaptan hidden molecular mechanisms, in order to also understand, the remain altered pathways.

Methods

Quantitative proteomics based on SWATH–MS technology were performed comparing proteomes of kidneys from polycystic kidney disease (PKD) murine model: Pkd1cond/cond;Tam-Cre−/+. Mice were subdivided in three groups: Wild Type, Mutant and Tolvaptan-treated mutant animals.

Results

In this study, tolvaptan showed an amelioration of renal function measured by BUN, as well as diminution in cystic index and number of cysts. Through quantitative proteomics, we identified a list of 327 proteins with and adjusted p-value below 0.05 and two-fold cut-off which were found to be modified after tolvaptan treatment in comparison to mutant animals and 433 proteins in tolvaptan-treated group in comparison with wild type animals. In both differential proteomes tolvaptan treatment has shown a differential expression in the cluster of respiratory electron transport and ATP synthesis by proteins of the inner membrane of mitochondria, which could indicate a reduction in the oxygen necessities after the treatment. This effect can reduce hypoxia in cystic environment, which in turn can be responsible for some of the beneficial effects of the drug.

Conclusion

This work identified novel molecular pathways modified after tolvaptan treatment such as diminution in oxygen necessities and downregulation of proteins responsible for ATP synthesis. These modifications elucidate crucial aspects of tolvaptan treatment, unmasking novel alternative or complementary treatment strategies for ADPKD.